Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
186Rhenium Nanoliposomes in Recurrent Glioma
NCT01906385Phase 2Recruiting
- Sponsor
- Cerenome
- Start
- Jun 2015
- Primary completion
- Apr 2027
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rhenium-186-obisbemeda in glioma, sponsored by Cerenome. Primary endpoints: Maximum Tolerated Dose at 90 days and Overall Survival at 12 months. Started Jun 2015; status: recruiting.
02
Drugs
rhenium-186-obisbemeda
03
Conditions
glioma
Beyond the preview
Go deeper on NCT01906385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01906385.